|
Last
Update:
November 19, 2008
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
Ninth International Congress on Drug Therapy in HIV Infection
|
-
Efficacy and safety of TDF/FTC-containing first-line HAART in clinical practice
– 2-year data
from the German Outpatient Cohort
van Lunzen J, Fätkenheuer G, Lutz T, et al
Abstract
-
Similar virological
response rates for ART-naïve subjects starting KVX + LPV/r or TVD+ LPV/r.
Data from the prospective observational STAR cohort
Wolf E, Trein A, Schmidt W, Baumgarten A, et
a
Abstract
-
Cost-effectiveness of
tenofovir/emtricitabine compared with other NRTI pairs in treatment-naïve adults
with HIV infection in the USA
Brogan AJ, Everhard F, Talbird SE, et al
Abstract
-
The TOKEN study:
safety and efficacy of Truvada or Kivexa in combination with efavirenz in
treatment-naïve
predominantly black African HIV patients
Das S, Arumainayagam J, Kumari B, et a
Abstract
-
Efficacy and safety of
tenofovir/emtricitabine compared to abacavir/lamivudine in HIV-1 infected
patients in
clinical setting. The TEAL study
Eccleston KJ, Bambumba A, Babu CS, et al
Abstract
-
Immune and virologic
responses to Truvada or Combivir as a first-line therapy of HIV-infected,
treatment-naïve patients
Maserati R, Clerici M, Lauriola M, et al
Abstract
-
Efficacy and safety of
Truvadain HIV-1 pregnant women: report of 23 cases
Ciraru-Vigneron N, Mazeron
MC, Lefevre V, et al
Abstract
XVII International AIDS Conference
|
-
One year comparative hematological and renal safety of tenofovir +
emtricitabine versus zidovudine +
amivudine in HIV-1 infected patients on first line nevirapine or efavirenz
based therapy in Thailand
G. Jourdain B. Leurent, V. Klinbuayaem, et al
Abstract
-
Transform: alterations in fat distribution over 48 weeks following
substitution of tenofovir DF/emtricitabine
for didanosine/lamivudine in HIV-infected patients on a common efavirenz
background
D. Park, C.
Jennings, C. Taylor, et al
Abstract
-
Simplification with easier emtricitabine and tenofovir (SWEET): results of a 48
week analysis of patients’
perceptions of treatment and adherence
V.L. Cooper, R. Horne, G. Moyle, et al
Abstract
-
The LOLITA trial: a pilot study assessing the safety and adherence of a once
daily regimen including tenofovir
and emtracitabine (TDF+FTC), boosted atazanavir (ATV) as a post exposure
prophylaxis (PEP)
J.-M. Livrozet, N. Berra, F. Brunel, et al
Abstract
-
Renal function in treatment-naive subjects exposed to tenofovir (TFV)/
emtricitabine in combination with
atazanavir/ritonavir (ATV/r) or lopinavir/ritonavir (LPV/r): 48-week results
from the CASTLE study (BMS AI424138)
D.
McGrath, L. Zhu, A. Thiry, et al
Abstract
4th IAS Conference on HIV Pathogenesis,
Treatment
and Prevention |
|
Efficacy and safety of NRTI´s switch to tenofovir plus emtricitabine
(Truvada(R)) vs. abacavir plus
lamivudine (Kivexa(R)) in patients with virologic suppression receiving a
lamivudine containing HAART:
the BICOMBO study
Martinez E., Arranz JA, Podzamczer D.
Abstract
Efficacy of tenofovir/emtricitabine containing ART regimen in cerebrospinal
fluid (CSF)
Nolting T., Arendt GR.
Abstract
Better adherence to both tenofovir/emtricitabine and to efavirenz in
individuals taking tenofovir/
emtricitabine fixed dose nucleoside combination tablet
Keiser P., Armas L., Sanchez J, et al
Abstract
8th Int Congress on Drug Therapy in HIV
Infection
|
|
Truvada Main Page
